18 Nov

Sarepta Rises 5.3%, Helping XBI’s Small-Cap Stocks


XBI small-caps muted by large and mid-cap stocks

The small-cap (small capitalization) stocks of the SPDR S&P Biotech ETF (XBI) gained 0.5% on November 17, 2015. XBI’s small-cap stocks underperformed its large-caps, its mid-caps, and XBI itself. However, the small-cap stocks outperformed the SPDR S&P 500 ETF (SPY), which gave a return of -0.05%.

As of November 17, 2015, XBI has 60 small-cap stocks in its portfolio with a market capitalization ranging from $300 million to $2 billion. Small-cap stocks account for ~57.8% of XBI’s portfolio. Out of 60 stocks, 22 ended up in the red and 38 gave positive returns.

Sarepta Rises 5.3%, Helping XBI’s Small-Cap Stocks

XBI’s small-cap stocks include Amicus Therapeutics (FOLD), AMAG Pharmaceuticals (AMAG), and Merrimack Pharmaceuticals (MACK), which gave returns of -6.8%, 4.5%, and 4.7%, respectively.

The above graph reflects the collective performance of XBI’s small-cap stocks in comparison with XBI and SPY. Since the beginning of November 2015, XBI’s small-cap stocks have given a return of 3%, while XBI returned 3.3% and SPY returned -1.2%. The small-caps underperformed XBI but outperformed SPY.

Sarepta announces positive data for eteplirsen, gains 5.3%

Sarepta Therapeutics (SRPT) gained 5.3% on positive data for the drug eteplirsen.

As per its press release, SRPT announced, “The Annals of Neurology published online positive efficacy and safety results from a Phase IIb long-term open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy (or DMD) amenable to exon 51 skipping. The study found that at three years of treatment, patients experienced a slower rate of disease progression when compared to untreated matched historical controls and the investigational drug continued to be well-tolerated.”

SRPT closed at $27.3 and was trading below its 50- and 100-day moving averages. SRPT witnessed high trading volumes, with ~1.8 million shares being traded as compared to its five-day average trading volume of ~884,000 shares per day.

SRPT has a book value of $2.94. With its current price, the stock is trading at a price-to-book value (or PBV) of 9.30x. SRPT has a weight of 1.4% in XBI’s portfolio.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.